HDA2 Inhibitors

The chemicals designed to inhibit HDA2 operate mainly by interfering with the catalytic domain responsible for its deacetylase activity. For instance, Trichostatin A and Vorinostat are both HDAC inhibitors that act on Class I and II HDACs, effectively blocking HDA2's capacity to remove acetyl groups from histone and non-histone proteins. This disruption leads to an increase in acetylated histones, thereby affecting the regulatory roles HDA2 plays in gene expression. Sodium Butyrate, a short-chain fatty acid, also blocks deacetylation activity of Class I and II HDACs including HDA2, causing a decrease in gene silencing mediated by this protein. Similarly, Mocetinostat and Apicidin are isotype-selective and Class I HDAC inhibitors, respectively, that impede HDA2's enzymatic domain, leading to altered epigenetic regulation.

On the other hand, Panobinostat and Belinostat are pan-HDAC inhibitors that broadly disrupt the enzymatic activities of multiple HDACs, including HDA2. Their inhibition increases acetylation of histones, which in turn alters gene expression profiles. Specificity towards Class I HDACs is a characteristic of Entinostat and Romidepsin, both of which directly affect HDA2's deacetylation function, causing increased acetylation and consequent disruption in gene regulation. Second-generation HDAC inhibitors like JNJ-26481585 are designed to target multiple HDACs while maintaining higher potencies. In the case of HDA2, this leads to altered gene repression typically mediated by this protein. Tubastatin A, although less potent on HDA2, can still affect it through cross-reaction, disrupting its role in gene regulation by increasing acetylation levels.